---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-24-000010"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T08:57:56.733383+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gilead Q1 GAAP loss per share $(3.34) on $3.9B CymaBay charge; guidance slashed

## Summary
- GAAP diluted EPS loss $(3.34) vs $0.80 YoY; non-GAAP loss $(1.32) vs $1.37.
- Revenue up 5% to $6.7B; base business ex-Veklury up 6% to $6.1B.
- Biktarvy up 10% to $2.9B; Oncology up 18% to $789M.
- Full-year GAAP EPS guidance cut to $0.10–$0.50 from $5.15–$5.55; non-GAAP to $3.45–$3.85 from $6.85–$7.25.
- Cash $4.7B; operating cash flow $2.2B; dividends paid $990M; $400M stock buyback.

## SEC filing metadata
- accession: 0000882095-24-000010
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/0000882095-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/gild-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-24-000010
- JSON: https://secwatch.observer/filing/0000882095-24-000010.json
- Plain text: https://secwatch.observer/filing/0000882095-24-000010.txt

## Key facts
- Earnings Releases
  GILEAD SCIENCES, INC. reported the quarter ended March 31, 2024 results: revenue $6.7 billion, EPS $(3.34).
  - Period: the quarter ended March 31, 2024
  - Revenue: $6.7 billion
  - EPS: $(3.34)
  - Result: reported results
  source text: providing updates on this and our broad Oncology portfolio throughout the rest of 2024.” First Quarter 2024 Financial Results • Total first quarter 2024 revenue increased 5% to $6.7 billion, compared to the same period in 2023, primarily due to higher HIV, Oncology and Liver Disease sales. • Diluted (loss) earnings per share (“EPS”) was $(3.34) in the first quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/0000882095-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.